Table 3.
Mean Annual Costs (EUR) of Primary Care Patients With at Least 1-Year Persistence (Glargin Versus NPH).
| Variable | Glargin costs prior ID | Glargin costs post ID | NPH costs prior ID | NPH costs post ID | Cost difference (glargin vs NPH) |
|---|---|---|---|---|---|
| N | 1342 | 1342 | 1342 | 1342 | |
| Total treatment costs | 764 (499) | 1166 (596) | 686 (444) | 1160 (645) | −48 (22); P = .0288a |
| Diabetes-related prescription costs | 506 (443) | 907 (553) | 451 (393) | 908 (566) | −49 (19); P = .0109 |
| Insulin, oral/injectable antidiabetics | 447 (414) | 676 (444) | 380 (351) | 647 (430) | — |
| Consumables | 59 (110) | 232 (253) | 72 (145) | 261 (293) | — |
| Treatment of hypoglycemia (glucagon i.m., glucose i.v.) | 0.0 (0.0) | 0.0 (0.9) | 0.0 (0.9) | 0.1 (2.3) | — |
| Other medical services | 258 (251) | 259 (212) | 235 (212) | 252 (235) | +7 (8); P = .3782 |
Data are means (SD). Patients with and without discontinuation were propensity score matched for age, sex, diabetes duration, diabetologist care, disease management program participation, and Charlson Comorbidity Index; cost differences were further adjusted for baseline costs and HbA1c. ID, index date of starting basal insulin therapy. Cost difference (last column): positive values represent savings; negative values are excess expenditure.
a
P values: difference (glargin versus NPH) of costs differences (post/prior ID).